Cleerly’s AI: De-Risking CCTA for Investors and Clinicians

The world of cardiovascular AI is producing new diagnostic tools at a breakneck pace, but getting them through the complex regulatory maze is another story entirely. For clinicians, investors, and hospital buyers trying to make sense of it all, you have to understand exactly what a specific AI tool does and what its FDA status really means. Let’s dig into Cleerly, a company that’s all over the news for its AI-driven analysis of coronary computed tomography angiography (CCTA), and dissect how its FDA-cleared software works and where it fits in the larger cardiac AI market.

The Core of Cleerly: AI-Driven CCTA Analysis

At its heart, Cleerly’s technology is built to do one thing: analyze coronary CT angiography (CCTA) scans with AI. This isn’t one of those platforms that pulls data from a smartwatch, monitors health through an app, or tries to manage medications. Cleerly is squarely in the diagnostic imaging analysis camp. Its software is designed to give a detailed, quantitative breakdown of coronary plaque, stenosis, and the probability of ischemia, all pulled directly from CCTA images. This gives doctors objective, repeatable numbers instead of just a qualitative read, which is a big step toward true precision cardiology. The American College of Cardiology (ACC) and American Heart Association (AHA) already gave CCTA a Class 1, Level A evidence recommendation in their 2021 guidance for checking out chest pain patients ACC/AHA 2021 CCTA Guidelines. Cleerly’s AI simply takes that established test and makes it much more powerful and easier to interpret.

Working through the FDA Field: 510(k) Clearance and Breakthrough Designation

Cleerly’s path to market shows the different ways AI medical devices can get through the FDA. The company has hit two major regulatory milestones, and they mean very different things. First, in January 2024, Cleerly ISCHEMIA got FDA 510(k) clearance. This positions the software as an automated decision-support tool that helps spot likely ischemia on CCTA scans Cleerly ISCHEMIA FDA 510(k) press release. A 510(k) is the most common path for Software as a Medical Device (SaMD), demonstrating that the new product is “substantially equivalent” to something already on the market. That clearance is the ticket to market entry, letting hospitals deploy Cleerly ISCHEMIA as a regulated diagnostic tool to help guide treatment decisions. Being able to automatically flag ischemia from a CCTA scan is a huge time-saver and could reduce the need for more invasive or radiation-heavy follow-up tests. Second, and completely different, Cleerly’s CAD Staging System got an FDA Breakthrough Device Designation in March 2024. This isn’t a green light to sell the product. It’s an expedited program for devices that could offer a better way to diagnose or treat life-threatening diseases. Getting this designation gives a company priority review and more direct interaction with the FDA. For a company, it shows the FDA agrees the technology has the potential to be a major clinical step forward. This system is meant to classify coronary artery disease in much more detail than just “yes” or “no,” using a staging system based on plaque types and total disease burden. For investors, a Breakthrough designation helps de-risk the long regulatory road and can point to better reimbursement down the line, like being eligible for New Technology Add-On Payments (NTAP) once it’s finally approved.

Plaque Quantification and Ischemia Detection: The AI Methodology

What Cleerly’s AI does so well is look deeper than the human eye can during a routine CCTA review. The software uses machine learning to digitally trace and analyze the coronary arteries, carefully quantifying the different kinds of plaque (calcified, non-calcified, and the particularly dangerous low-attenuation plaque) while also measuring the percentage of stenosis. This gives doctors hard data that can be used to track whether a patient’s disease is getting worse or better over time, a precision that’s almost impossible to get from visual reads alone. To figure out the risk of ischemia, the Cleerly ISCHEMIA software takes all that plaque data and combines it with anatomical information from the CCTA. It crunches these numbers to produce a probability that a blockage is actually restricting blood flow, which turns the CCTA into a non-invasive functional assessment. This is incredibly useful for figuring out which patients really need a stent or more aggressive therapy, fitting right into the push for personalized medicine in cardiology. The AI’s report acts as clinical decision support, giving cardiologists more confidence in their diagnosis and helping to simplify the patient’s care plan.

Distinguishing Diagnostic Imaging AI in the Cardiac AI Ecosystem

It’s really important not to lump all “cardiac AI” into one bucket. The space is huge and contains very different types of technology:

• Wearable/App-Based Monitoring: This is your consumer-grade stuff, pulling ECG, heart rate, and activity data from wearables to look for arrhythmias or just track general health. It’s all about continuous, passive monitoring.
• Medication Management AI: These are platforms that dig through electronic health records (EHRs) to optimize drug choices, predict if a patient will take their pills, or flag potential bad reactions.
• Diagnostic Imaging Analysis (e.g., Cleerly): This is the category Cleerly lives in. The AI here is built to interpret complex medical images like CCTA, MRI, or Echo scans to deliver hard diagnostic numbers. This group has a direct effect on a doctor’s diagnosis and treatment plan based on what they see in the images. This isn’t just a semantic difference. It has major consequences for FDA oversight, how companies get paid, and how the tool fits into a hospital’s workflow. Diagnostic imaging AI for a serious condition like coronary artery disease goes through intense regulatory review, usually needing a 510(k) or De Novo classification. The standards for clinical proof are sky-high, requiring solid data on accuracy, reproducibility, and whether the tool actually improves patient outcomes. So, for hospital buyers looking at cardiac AI tools, understanding which category a product falls into is the first step to figuring out its clinical value, regulatory maturity, and potential ROI. Cleerly’s tight focus on CCTA analysis makes it a specialized, high-precision tool for a very specific diagnostic problem, and it’s a world away from general-purpose or consumer-facing AI in cardiology.
  

  Conclusion

Cleerly’s work in AI-driven CCTA analysis represents a real shift in how we approach cardiovascular diagnostics. By delivering objective, quantitative data on coronary plaque and ischemia, its FDA-cleared and Breakthrough-designated products give clinicians better tools for making a precise diagnosis and managing patient care. This type of specialized AI, which focuses on diagnostic imaging, is a very specific and heavily regulated part of the cardiac AI field. It’s exactly this kind of application that will redefine how we find, understand, and treat coronary artery disease. As the cardiac AI market keeps growing, it will be solutions like Cleerly, backed by strong evidence and regulatory approval, that truly push AI-assisted cardiology forward.